Hypokalemia: Causes, Symptoms, Treatment

Hypokalemia is a decrease in serum potassium concentration below 3.5 millimoles per liter. Potassium is a key intracellular cation that determines the electrical stability of the myocardium and conduction system, the excitability of neuromuscular tissue, and the function of renal tubules. Even a moderate decrease in potassium increases the risk of arrhythmias, especially when combined with hypomagnesemia or the use of antiarrhythmics, diuretics, or glucocorticoids. Therefore, timely recognition and correction of potassium deficiency is an important task in primary and hospital care. [1]

Clinical manifestations vary widely, from asymptomatic to muscle weakness, seizures, paresis, and life-threatening ventricular arrhythmias. The severity of symptoms depends not only on the absolute potassium level but also on the rate of its decline, concurrent magnesium shifts, acid-base balance, and the presence of coronary artery disease and heart failure. Electrocardiographic changes—flattening or inversion of the T wave, ST segment depression, prominent U waves, and prolongation of the QU interval—serve as early clues. [2]

Pathophysiologically, hypokalemia develops due to potassium loss (via the kidneys or gastrointestinal tract), potassium redistribution from the extracellular space into cells, and inadequate dietary intake. In most adults, drug-induced and renal losses predominate, as do diuretic-induced losses, secondary hyperaldosteronism, and tubulopathies, as do hypokalemia associated with hyperthyroidism and periodic paralysis. Magnesium deficiency perpetuates potassium loss and makes therapy "refractory" if magnesium is not replenished. [3]

The practical approach always follows a single algorithm: confirm hypokalemia, assess its severity and ECG, determine whether the losses are renal or extrarenal, identify the mechanism (loss, redistribution, deficiency), and initiate targeted correction while simultaneously monitoring magnesium levels. This step-by-step approach reduces errors and prevents dangerous arrhythmias. [4]

Code according to ICD-10 and ICD-11

In the International Classification of Diseases, Tenth Revision, hypokalemia is coded under the heading E87.6 "Hypokalemia." If necessary, an additional cause is indicated (e.g., "side effect of diuretics" or "nutritional deficiency"), which ensures clinical and statistical accuracy of the recording. Related headings of E87 also include other water-electrolyte disturbances that often coexist with hypokalemia, such as hypomagnesemia and acid-base imbalance. [5]

In the International Classification of Diseases, Eleventh Revision, hypokalemia is classified under the heading "Disturbances of Water, Electrolyte, or Acid-Base Balance" and is coded as 5C70.1 "Hypokalemia." If desired, the underlying condition can be additionally coded: tubulopathy, hyperaldosteronism, laxative or diuretic abuse, or hyperthyroidism. This level of detail facilitates analysis of the underlying cause and prevention planning. [6]

Table 1. Correspondence of ICD codes

Term	ICD-10	ICD-11
Hypokalemia	E87.6	5C70.1
Water and electrolyte imbalance, others	E87.*	5C7* (relevant subheadings)
Side effects of diuretics	Y54.2 (if necessary)	XC9M (adverse drug reaction, if necessary)

Epidemiology

Hypokalemia is one of the most common electrolyte disturbances in hospitals. In large reviews, the prevalence among hospitalized patients ranges from approximately 2.6% to 23.2%, reaching approximately 49.9% in emergency department patients and up to 56% with certain treatment regimens (e.g., diuretic therapy). The variability is explained by differences in criteria, department profiles, and monitoring intensity. [7]

Mild hypokalemia is less common in outpatient practice, but is still observed in approximately 10-14% of patients examined based on individual laboratory panel data. It accounts for a significant proportion of visits with complaints of muscle weakness, paresthesia, and cardiac arrhythmia, especially in patients taking thiazide diuretics. [8]

In high-risk groups—the elderly, patients with heart failure, cirrhosis, chronic respiratory diseases, and diabetes—hypokalemia is more common and is associated with increased hospital mortality and length of stay. Hypokalemia is particularly dangerous in patients with acute coronary syndromes and a long QT interval. [9]

Thyrotoxic periodic paralysis occupies a distinct epidemiological niche: it occurs more frequently in men of Asian descent and often debuts between 20 and 40 years of age, with episodes of weakness that can even lead to plegia. Recognizing this phenotype is important because it requires a different approach than that of typical deficiency hypokalemia. [10]

Table 2. Prevalence of hypokalemia by sources

Environment/cohort	Prevalence assessment
Hospitals (total)	2.6-23.2%
Urgent Care	up to 49.9%
Outpatient panels	about 10-14%
With diuretic therapy (separate cohorts)	up to 56%

Reasons

Gastrointestinal losses include diarrhea, vomiting, laxative abuse, and long-term fistulas and drainage. Vomiting causes little direct potassium loss, but metabolic alkalosis and chloride deficiency develop with secondary increases in renal potassium excretion (potassium follows sodium in the distal nephron). These mechanisms are particularly pronounced in the presence of magnesium deficiency and secondary hyperaldosteronism. [11]

Renal losses: diuretics (thiazide and loop), hyperaldosteronism, renovascular hypertension, tubulopathies (Bartter and Gitelman syndromes), osmotic diuresis, nephropathy with tubular damage. Gitelman is characterized by a combination of hypokalemia, metabolic alkalosis, hypomagnesemia, and hypocalciuria - an important guideline in the outpatient clinic. [12]

Redistribution of potassium into the cell: thyrotoxic periodic paralysis, catecholamine surges, beta-agonist overdose, insulin therapy for hyperglycemia, alkalemia. In these cases, the total potassium reserve may be close to normal, and the decrease in serum levels may be transient; excessive potassium administration in such cases is fraught with "rebound" hyperkalemia. [13]

Insufficient intake: a rare isolated cause (starvation, severe dietary restrictions), but when combined with losses or redistribution, it exacerbates the deficiency. In the elderly, combined scenarios are common: a poor diet, diuretics, and diarrhea, together, lead to clinically significant hypokalemia. [14]

Risk factors

Medications: thiazides and loop diuretics, glucocorticoids, amphotericin, some high-dose penicillins, beta-agonists, insulin during aggressive correction of hyperglycemia. Combinations of several drugs increase the risk, especially in the elderly and in patients with chronic kidney disease. [15]

Hypomagnesemia is a common "hidden" factor. It activates potassium channels in the distal nephron, increasing potassium loss; without magnesium replacement, potassium is not retained or replenished, as confirmed by clinical observations. Therefore, magnesium assessment and correction are a mandatory part of therapy. [16]

Hormonal and acid-base influences: hyperaldosteronism, Cushing's syndrome, alkalemia, hyperthyroidism (including thyrotoxic periodic paralysis). The risk is particularly high when combined with high distal sodium delivery (e.g., with diuretics). [17]

Clinical situations: heart failure, cirrhosis, chronic obstructive pulmonary disease (beta-agonists), diabetes mellitus with insulin and glycemic fluctuations, alcoholism, and malnutrition. Treatment protocols in these groups should include regular potassium monitoring. [18]

Table 3. Risk factors for persistent hypokalemia

Factor	Mechanism
Diuretics	Distal sodium delivery, secondary hyperaldosteronism
Hypomagnesemia	Potassium loss through the ROMK channel; "refractory" to therapy
Hyperaldosteronism	Increased secretion of potassium in the collecting ducts
Thyrotoxicosis/beta-agonists/insulin	Redistribution of potassium into the cell

Pathogenesis

Potassium balance is maintained by intake, distribution between sectors, and excretion. The kidneys excrete excess potassium in the distal nephrons under the influence of aldosterone and sodium flux. Any process that increases distal sodium intake (diuretics, osmotic diuresis) increases potassium loss; aldosterone "tunes" the channel system to secrete potassium. [19]

Hypomagnesemia removes the "brake" on ROMK potassium channels, increasing urinary potassium loss. While magnesium levels are low, intracellular potassium is not retained: this explains why potassium supplementation without magnesium correction produces a short-term effect. This phenomenon has been described both experimentally and clinically. [20]

Potassium redistribution depends on the activity of sodium-potassium adenosine triphosphatase and the acid-base balance: insulin and beta-adrenergic stimulation "drive" potassium into cells; alkalemia enhances this shift. In thyrotoxic periodic paralysis, hyperactivation of the sodium-potassium pump and an increased insulin response lead to rapid episodes of hypokalemia with muscle weakness. [21]

In tubulopathies, sodium/chloride transport is impaired in certain segments of the nephron. For example, in Gitelman syndrome, a defect in the sodium-chloride transporter in the distal tubule causes chronic salt wasting, hyporeninemic hyperaldosteronism, metabolic alkalosis, hypokalemia, and hypomagnesemia. [22]

Symptoms

Mild hypokalemia is often asymptomatic. As levels decrease, muscle weakness, fatigue, myalgia, cramps, and paresthesia occur. Severe hypokalemia can manifest as rhabdomyolysis and paralytic ileus. [23]

Cardiac manifestations include irregular heartbeats, increased heart rate, and episodes of presyncope. The electrocardiogram typically shows flattening or inversion of the T wave, ST segment depression, prominent U waves, and prolongation of the QU interval, which predisposes to supraventricular and ventricular arrhythmias, including torsades de pointes. [24]

Thyrotoxic periodic paralysis is characterized by acute episodes of weakness or paralysis, often following a carbohydrate load or physical exertion, with markedly reduced potassium and preserved phosphate levels. Patients may be asymptomatic between episodes. Treatment differs from routine potassium supplementation. [25]

In tubulopathies, symptoms are often chronic and nonspecific: cramps, orthostatic symptoms, salt cravings, paresthesia, and sometimes arrhythmia. The combination of hypokalemia with hypomagnesemia and low calciuria is a clue to Gitelman syndrome. [26]

Table 4. Typical ECG signs of hypokalemia

Sign	Description
Flattening/inversion T	Decreased ventricular repolarization
ST depression	"Pseudoischemic" changes
U-wave	Pronounced in severe hypokalemia
QU extension	Risk of torsades de pointes and fatal arrhythmias

Classification, forms and stages

By severity: mild (3.0-3.4 millimoles per liter), moderate (2.5-2.9 millimoles per liter), severe (<2.5 millimoles per liter). However, clinical assessment takes into account not only the numbers, but also symptoms, ECG, and the rate of decline in levels. The need for urgent assistance increases in the presence of arrhythmias, coronary heart disease, and a prolonged QT interval. [27]

By mechanism: extrarenal and renal losses; redistribution; insufficient intake. This block helps narrow the search and select urine tests. Often, mechanisms are combined, for example, diarrhea plus diuretics. [28]

By context: drug-induced (diuretics, beta-agonists), hormonal (hyperaldosteronism, thyrotoxicosis), genetic (Gittelman, Bartter), iatrogenic (insulin therapy, alkaline infusions for alkalosis). This "etiological" classification facilitates the prevention of relapses. [29]

Treatment resistance: "refractory" hypokalemia against a background of hypomagnesemia, ongoing losses, or uncorrected hormonal drive (aldosterone, thyroid hormones). In these cases, simply administering potassium is insufficient. [30]

Complications and consequences

Cardiac: supraventricular and ventricular arrhythmias, including atrial fibrillation, ventricular tachycardia, ventricular fibrillation, and torsades de pointes. The risk is particularly high with concomitant prolongation of the QT interval, coronary artery disease, and use of class III antiarrhythmic drugs. [31]

Neuromuscular: myopathy, rhabdomyolysis, paralysis (including thyrotoxic periodic paralysis), intestinal atony. These complications are more common with severe and rapidly developing hypokalemia. [32]

Renal: nephrogenic concentrating failure, polyuria, metabolic alkalosis, tubulointerstitial changes in chronic deficiency. Patients with chronic diseases have a higher risk of progression of the condition. [33]

In-hospital outcomes: increased length of hospital stay, need for intensive monitoring, incidence of serious events, and mortality in vulnerable groups. This supports the need for early detection and intervention protocols. [34]

When to see a doctor

Immediately - if you experience palpitations, irregular heartbeats, syncope, increasing shortness of breath, weakness, sudden paresis or plegia, convulsions, or severe muscle pain (suspected rhabdomyolysis). These signs may indicate severe hypokalemia with a risk of arrhythmia. [35]

In the coming days - if you experience persistent muscle weakness, cramps, or fatigue, especially if you are taking diuretics, beta-agonists, insulin, laxatives, or have diarrhea. Early monitoring of potassium and magnesium levels can help prevent complications. [36]

If hyperthyroidism is known and episodes of weakness occur after carbohydrate loading or physical activity, thyrotoxic periodic paralysis must be urgently excluded: the tactic is different from the usual “infusion” of potassium. [37]

Patients with arrhythmias, prolonged QT interval, and coronary heart disease are advised to regularly check potassium and magnesium, especially when changing therapy. [38]

Diagnostics

The first step is to confirm the level and assess the severity: blood tests for potassium, magnesium, blood gases, and acid-base balance, and an electrocardiogram (ECG) to look for U waves and ST depression. A drug history is also collected, and gastrointestinal losses are clarified. Emergency "red flags" require monitoring and correction until a full evaluation is completed. [39]

The second step is to determine whether potassium is being lost through the kidneys. Two useful indicators are a urinary potassium concentration >15 millimoles per liter or a spot urine potassium-to-creatinine ratio >13 milliequivalents per millimoles of creatinine—both indicate inappropriately high renal losses. They are reliable and do not require 24-hour urine collection. [40]

The third step is to calculate the transtubular potassium gradient (TTKG), if necessary, to assess potassium secretion in the collecting ducts: values <3 suggest the absence of renal loss, and >7 suggest its presence. An important condition for applicability is that urine osmolality must not be lower than plasma osmolality, otherwise the indicator is invalid. [41]

The fourth step is an etiologic search: magnesium (and its correction), renin and aldosterone activity in hypertension, glucose and insulin (redistribution), thyroid hormones if thyrotoxic periodic paralysis is suspected, screening for tubulopathies (magnesium, urinary calcium, genetics if indicated). In persistent hypokalemia in a young adult with seizures and low calciuria, consider Gitelman syndrome. [42]

Table 5. Mini-algorithm for determining the source of losses

Indicator	Meaning	Interpretation
Urine potassium	>15 mmol/L	Renal losses are likely
Potassium/creatinine (spot urine)	>13 mEq/mmol	Renal losses are likely
TTKG	<3 / >7	<3 - extrarenal or redistribution; >7 - renal losses (under valid conditions)

Differential diagnosis

"Losses versus redistribution": the presence of diarrhea, vomiting, diuretics, and high renal losses indicate a true deficiency; acute thyroid attack, insulin therapy, and beta-agonists indicate redistribution. With redistribution, the total potassium stores may be close to normal, which affects the volume of replenishment. [43]

Renal versus extrarenal losses: We focus on urine potassium and the potassium-to-creatinine ratio. High values indicate renal losses (diuretics, hyperaldosteronism, tubulopathy), low values indicate extrarenal losses (diarrhea). TTKG is helpful if osmolality conditions are met. [44]

"Primary hyperaldosteronism versus diuretics": In patients with hypertension and hypokalemia without diuretics, screen for primary hyperaldosteronism. False interpretation is possible when taking diuretics; if possible, repeat tests after discontinuing the drug and use additional markers. [45]

Gitelman vs. Bartter: Gitelman is characterized by hypomagnesemia and low calciuria, while Bartter is characterized by normo/hypermagnesemia and hypercalciuria. Both variants result in metabolic alkalosis and chronic hypokalemia, but require different management and monitoring. [46]

Table 6. Rapid differences in the main phenotypes

Phenotype	Magnesium	Calcium in urine	Acid-base status
Gitelman syndrome	Short	Low (hypocalciuria)	Alkalosis
Bartter's syndrome	Usually normal	High (hypercalciuria)	Alkalosis
Diuretics (thiazides/loop)	Variable	Variable	Alkalosis
Diarrhea	Normal/low	Norm	Acidosis/normal

Treatment

The first line is an emergency assessment. In cases of severe hypokalemia (<2.5 millimoles per liter), symptoms, coronary artery disease, significant ECG changes, or concomitant hypomagnesemia, monitoring, cardiac monitoring, intravenous resuscitation, and parallel correction of the underlying cause are necessary. In stable conditions and mild/moderate hypokalemia, oral forms are preferred. Any treatment begins with discontinuation or correction of provoking factors (diuretics, laxatives, beta-agonists, high-dose insulin). [47]

Oral replacement is the treatment of choice for mild to moderate hypokalemia. Typical regimens are 10-20 milliequivalents 2-4 times daily for levels 3.0-3.4; for levels <3.0, 40 milliequivalents 3-4 times daily or 20 milliequivalents every 2-3 hours with rechecking after 2-4 hours. Potassium chloride is used more frequently because it corrects the chloride deficit in metabolic alkalosis. Monitor gastrointestinal tolerance; divide doses. [48]

Intravenous resuscitation is indicated for severe hypokalemia, arrhythmias, inability to take the drug or malabsorption. Recommended rates: up to 10 milliequivalents per hour via peripheral access under monitoring and up to 20 milliequivalents per hour via a central line under intensive observation and continuous ECG monitoring. Higher concentrations and rates are used only in intensive care with mandatory monitoring. [49]

Magnesium correction is crucial. For hypomagnesemia, magnesium sulfate is administered intravenously (for example, 1-2 grams, repeated as needed) or orally, since without normalizing magnesium, potassium is not maintained and its level quickly declines again. In treatments for "refractory" hypokalemia, magnesium is prescribed first or in parallel with potassium-containing medications. [50]

The choice of potassium salt depends on the acid-base status: in metabolic alkalosis, potassium chloride is preferred; in normal status, citrate or gluconate are possible (considering that citrate metabolically produces an alkaline equivalent). In patients with vomiting and chloride deficiency, administration of potassium chloride corrects the "maintenance" alkalosis. In diarrhea and acidosis, hydration and loss correction are advisable. [51]

Correcting the underlying cause is half the battle. Reduce the diuretic dose, switch to potassium-sparing agents (mineralocorticoid receptor antagonists, amiloride) if indicated, and add renin-angiotensin-aldosterone system inhibitors if needed for cardiorenal indications and potassium levels are controlled. For primary hyperaldosteronism, etiotropic treatment (adrenalectomy) or mineralocorticoid receptor antagonists are indicated. [52]

Thyrotoxic periodic paralysis requires a special approach: small and carefully titrated doses of potassium, early non-selective beta-blockers to inhibit the sodium-potassium pump, and mandatory treatment of thyrotoxicosis (antithyroid drugs, iodine, beta-blockers, and, if indicated, radioiodine or surgery). Aggressive potassium administration is dangerous due to "rebound" hyperkalemia after the attack. [53]

In tubulopathies (Gitelman), treatment is chronic: oral potassium and magnesium, and, if necessary, amiloride or spironolactone/eplerenone to reduce losses; dietary measures with adequate salt and potassium intake under control are important. Monitoring includes magnesium, potassium, blood pressure, and renal function. [54]

ECG-guided management: in the case of significant changes (high U waves, ST depression, QU prolongation), monitor and administer intravenous fluids, avoiding glucose-containing infusions, which will worsen hypokalemia due to insulin. At the same time, identify and correct any triggering factors: hypoxia, hypocapnia, pain, and anxiety. [55]

Treatment monitoring: reassess potassium after 2-4 hours with intensive replacement or within 24 hours with oral regimens; monitor magnesium, acid-base balance, and creatinine. After stabilization, a relapse prevention plan: adjust therapy, nutrition, education, and a self-monitoring plan. [56]

Table 7. Practical dosages and replenishment rates

Situation	Recommendation
Mild/moderate hypokalemia	10-20 mEq 2-4 times daily orally; control after 24 hours
<3.0 mmol/L without threat	40 mEq 3-4 times a day orally or 20 mEq every 2-3 hours
Severe/symptomatic	IV up to 10 mEq/h peripherally; up to 20 mEq/h centrally under ECG control
Mandatory accompanying measure	Magnesium correction (IV or oral)

Prevention

Rational drug therapy: minimizing diuretic doses, using potassium-sparing agents if necessary, monitoring potassium levels after increasing beta-agonist doses or initiating insulin therapy. In patients with hypertension and hypokalemia, consider screening for primary hyperaldosteronism. [57]

Diet and lifestyle: adequate potassium intake from foods (vegetables, fruits, legumes), adequate fluid intake, prevention of diarrheal episodes, moderation in laxatives. Patient education reduces the risk of relapses and hospitalizations. [58]

Medical monitoring: potassium and magnesium levels should be monitored in all patients receiving diuretics, glucocorticoids, beta-agonists, or who have chronic gastrointestinal losses. In hospitals, early notification protocols for critical values and corrective standards should be established. [59]

Specific measures: in patients with thyrotoxicosis - control of thyroid hormones and timely therapy; in tubulopathies - long-term observation and maintenance therapy with magnesium and potassium. [60]

Forecast

With timely correction, hypokalemia is reversible, and the prognosis is favorable. The risk of complications is determined by the severity of the deficiency, the rate of its development, concomitant hypomagnesemia, and cardiac background. Recurring episodes indicate an unaddressed cause and require further investigation. [61]

In high-risk patients (coronary artery disease, heart failure, prolonged QT interval), even moderate hypokalemia increases the likelihood of arrhythmias, so target potassium levels are often set closer to the upper limit of normal. Magnesium monitoring further reduces arrhythmogenicity. [62]

In thyrotoxic periodic paralysis, attacks cease once euthyroidism is achieved. In tubulopathies, outcome is determined by adherence to lifelong therapy and regular monitoring. [63]

In hospitals, implementation of electrolyte protocols reduces the length of hospital stay and the risk of adverse events, particularly in emergency and intensive care units where hypokalemia is more common.[64]

FAQ

Should everyone receive intravenous potassium?
No. Oral forms are preferred for mild to moderate hypokalemia in stable patients. Intravenous forms are used for severe hypokalemia, symptoms, significant ECG changes, or inability to take the solution orally. [65]

Why aren't my potassium levels "rising" even though I'm getting it?
A magnesium deficiency is often the cause: without correction, continued renal potassium loss occurs. Other possibilities include ongoing losses (diarrhea, diuretics), uncorrected hormonal drive (aldosterone), or redistribution. [66]

How can potassium levels be increased quickly and safely?
Typically, 10-20 mEq orally 2-4 times a day; in severe hypokalemia, up to 10 mEq/h peripherally and up to 20 mEq/h centrally, under monitoring, should be administered intravenously. Magnesium levels are adjusted simultaneously, and glucose infusions, which can worsen hypokalemia, are avoided. [67]

Should thyrotoxic periodic paralysis be treated "like normal hypokalemia"?
No. The key here is non-selective beta-blockers and treatment of thyrotoxicosis; potassium is given carefully in small doses to avoid "rebound" hyperkalemia after redistribution stops. [68]

Table 8. Brief checklist for the doctor

Step	Action
1	Confirm levels, perform an ECG, assess symptoms and risk factors
2	Check your magnesium and begin correcting it if there is a deficiency.
3	Determine the source of losses (urine: potassium >15 mmol/L or potassium/creatinine >13 mEq/mmol; under valid conditions - TTKG)
4	Prescribe potassium replacement (orally or intravenously) and correct the cause
5	Review medications, educate the patient, and schedule follow-up appointments.